Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021888457> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2021888457 endingPage "190" @default.
- W2021888457 startingPage "190" @default.
- W2021888457 abstract "Lung cancer is a leading cause of death among adults. Non-small cell lung cancer (NSCLC) accounts for ∼85% of all lung cancer cases. For more than half of all patients diagnosis does not occur until the disease has metastasised. At this advanced stage, the 5-year survival rate is just 15%. Platinum-based chemotherapy forms the backbone of treatment for patients with advanced NSCLC and forms an important component of the therapeutic regimen for many patients with earlier stage disease. However, although a number of agents are available to partner the platinum-based compounds, treatment selection is largely empiric, and chemoresistance is a considerable barrier to improving outcomes. The identification of biologic and other markers to guide treatment selection, thus ensuring patients receive the most effective regimen for their individual tumour and avoid exposure to toxic agents from which they are unlikely to benefit, will be critical to improve outcomes for patients with NSCLC. The development of alternative agents for those patients who express predictors of a negative clinical response is of vital importance. A variety of biomarkers are emerging, including expression of DNA repair enzymes, ribonucleotide subunits and βIII tubulin. Treatment algorithms based on elucidation of such markers to guide treatment selection can already be envisaged. For example, those patients with high βIII tubulin expression should be considered for epothilone therapy as an alternative to taxane-based regimens. The epothilones may be preferred option as the evidence suggests that these agents retain activity versus taxane-resistant cancers. This paper reviews the evidence base for βIII tubulin expression as a prognostic and predictive biomarker in NSCLC and briefly explores the implications for clinical decision making of this and other emerging biomarkers." @default.
- W2021888457 created "2016-06-24" @default.
- W2021888457 creator A5004304726 @default.
- W2021888457 creator A5004708346 @default.
- W2021888457 creator A5013687413 @default.
- W2021888457 creator A5017572010 @default.
- W2021888457 creator A5021421298 @default.
- W2021888457 creator A5024831671 @default.
- W2021888457 creator A5055207921 @default.
- W2021888457 creator A5067225147 @default.
- W2021888457 date "2006-11-01" @default.
- W2021888457 modified "2023-10-14" @default.
- W2021888457 title "630 POSTER Inhibition of prostate xenograft growth by two novel orally bioavailable microtubule disruptors" @default.
- W2021888457 doi "https://doi.org/10.1016/s1359-6349(06)70635-8" @default.
- W2021888457 hasPublicationYear "2006" @default.
- W2021888457 type Work @default.
- W2021888457 sameAs 2021888457 @default.
- W2021888457 citedByCount "0" @default.
- W2021888457 crossrefType "journal-article" @default.
- W2021888457 hasAuthorship W2021888457A5004304726 @default.
- W2021888457 hasAuthorship W2021888457A5004708346 @default.
- W2021888457 hasAuthorship W2021888457A5013687413 @default.
- W2021888457 hasAuthorship W2021888457A5017572010 @default.
- W2021888457 hasAuthorship W2021888457A5021421298 @default.
- W2021888457 hasAuthorship W2021888457A5024831671 @default.
- W2021888457 hasAuthorship W2021888457A5055207921 @default.
- W2021888457 hasAuthorship W2021888457A5067225147 @default.
- W2021888457 hasConcept C121608353 @default.
- W2021888457 hasConcept C126322002 @default.
- W2021888457 hasConcept C143998085 @default.
- W2021888457 hasConcept C2776256026 @default.
- W2021888457 hasConcept C2777511904 @default.
- W2021888457 hasConcept C2779134260 @default.
- W2021888457 hasConcept C2780192828 @default.
- W2021888457 hasConcept C2781190966 @default.
- W2021888457 hasConcept C2781413609 @default.
- W2021888457 hasConcept C502942594 @default.
- W2021888457 hasConcept C530470458 @default.
- W2021888457 hasConcept C60644358 @default.
- W2021888457 hasConcept C71924100 @default.
- W2021888457 hasConcept C86803240 @default.
- W2021888457 hasConceptScore W2021888457C121608353 @default.
- W2021888457 hasConceptScore W2021888457C126322002 @default.
- W2021888457 hasConceptScore W2021888457C143998085 @default.
- W2021888457 hasConceptScore W2021888457C2776256026 @default.
- W2021888457 hasConceptScore W2021888457C2777511904 @default.
- W2021888457 hasConceptScore W2021888457C2779134260 @default.
- W2021888457 hasConceptScore W2021888457C2780192828 @default.
- W2021888457 hasConceptScore W2021888457C2781190966 @default.
- W2021888457 hasConceptScore W2021888457C2781413609 @default.
- W2021888457 hasConceptScore W2021888457C502942594 @default.
- W2021888457 hasConceptScore W2021888457C530470458 @default.
- W2021888457 hasConceptScore W2021888457C60644358 @default.
- W2021888457 hasConceptScore W2021888457C71924100 @default.
- W2021888457 hasConceptScore W2021888457C86803240 @default.
- W2021888457 hasIssue "12" @default.
- W2021888457 hasLocation W20218884571 @default.
- W2021888457 hasOpenAccess W2021888457 @default.
- W2021888457 hasPrimaryLocation W20218884571 @default.
- W2021888457 hasRelatedWork W1966409175 @default.
- W2021888457 hasRelatedWork W2085844047 @default.
- W2021888457 hasRelatedWork W2094570582 @default.
- W2021888457 hasRelatedWork W2155611965 @default.
- W2021888457 hasRelatedWork W2263206436 @default.
- W2021888457 hasRelatedWork W2735900144 @default.
- W2021888457 hasRelatedWork W2768013934 @default.
- W2021888457 hasRelatedWork W2776356588 @default.
- W2021888457 hasRelatedWork W2811161792 @default.
- W2021888457 hasRelatedWork W1503275640 @default.
- W2021888457 hasVolume "4" @default.
- W2021888457 isParatext "false" @default.
- W2021888457 isRetracted "false" @default.
- W2021888457 magId "2021888457" @default.
- W2021888457 workType "article" @default.